BRCA1 and triple-negative breast carcinoma: The aim of this paper is to evaluate the probability of pCR in triple-negative breast cancers patients, treated mostly with the recommended, neoadjuvant schedule AC followed by taxane chemotherapy, based on BRCA1 gene mutation status.